drugset / Trial / NCT06857227
A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis
Phase 1
Recruiting
54 enrolled
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a randomized controlled phase I clinical study with safety, efficacy, and pharmacokinetic/pharmacodynamic characteristics in patients with rheumatoid arthritis.
Timeline
- Start
- 2025-03-17
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GNC-038 | Monoclonal antibody | — | Intravenous |